Quick Answer
Disc Medicine, Inc. reported Net Income of -$212.18 million for fiscal year 2025.
Disc Medicine, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$212.18M -94.0% |
-$109.36M -43.1% |
-$76.43M -63.2% |
-$46.83M -30.2% |
-$35.97M +11.9% |
-$40.84M |
| Diluted EPS | -$6.01 -51.8% |
-$3.96 -15.8% |
-$3.42 +92.4% |
-$45.05 -10.0% |
-$40.95 | — |
| Total Assets | $806.88M +62.4% |
$496.77M +35.0% |
$368.00M +83.8% |
$200.21M +116.6% |
$92.41M +1010.8% |
$8.32M |
| Cash and Equivalents | $91.14M -52.6% |
$192.43M -46.6% |
$360.38M +85.2% |
$194.61M +121.1% |
$88.04M +1855.1% |
$4.50M |
| Long-Term Debt | $29.16M +3.0% |
$28.32M | $0.00 | — | — | — |
| Stockholders Equity | $739.83M +66.8% |
$443.59M +28.5% |
$345.12M +95.4% |
$176.60M +375.1% |
-$64.20M -122.9% |
-$28.81M -176.2% |
| R&D Expense | $170.64M +76.5% |
$96.67M +39.6% |
$69.26M +107.1% |
$33.44M +32.8% |
$25.17M -10.6% |
$28.17M |
| Operating Income | -$236.02M -81.9% |
-$129.72M -42.4% |
-$91.12M -91.9% |
-$47.48M -53.5% |
-$30.93M +9.1% |
-$34.04M |
| Shares Outstanding | 37.89M +26.9% |
29.87M +22.6% |
24.36M +40.0% |
17.40M -59.5% |
43.00M +176.2% |
15.57M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$62.32M | -134.3% | -12.8% |
| Diluted EPS | September 30, 2025 | -$1.77 | -98.9% | -12.0% |
| Total Assets | September 30, 2025 | $630.46M | +27.3% | -5.2% |
| Cash and Equivalents | September 30, 2025 | $140.66M | -27.0% | +10.5% |
| Long-Term Debt | September 30, 2025 | $28.95M | — | +0.7% |
| Stockholders Equity | September 30, 2025 | $573.39M | +22.5% | -6.6% |
| R&D Expense | September 30, 2025 | $50.33M | +103.9% | +8.7% |
| Operating Income | September 30, 2025 | -$67.70M | -106.0% | -10.2% |
| Shares Outstanding | September 30, 2025 | 35.01M | +17.7% | +0.9% |
- Disc Medicine, Inc. reported Net Income of -$212.18 million for fiscal year 2025.
- Disc Medicine, Inc. showed a decrease of -94.0% in Net Income compared to the prior fiscal year.
- Disc Medicine, Inc. reported Diluted EPS of $6.01 per share (loss) for fiscal year 2025.
- Disc Medicine, Inc. showed a decrease of -51.8% in Diluted EPS compared to the prior fiscal year.
- Disc Medicine, Inc. reported Total Assets of $806.88 million for fiscal year 2025.
- Disc Medicine, Inc. showed an increase of +62.4% in Total Assets compared to the prior fiscal year.
- Disc Medicine, Inc. reported Cash and Equivalents of $91.14 million for fiscal year 2025.
- Disc Medicine, Inc. showed a decrease of -52.6% in Cash and Equivalents compared to the prior fiscal year.
- Disc Medicine, Inc. reported Long-Term Debt of $29.16 million for fiscal year 2025.
- Disc Medicine, Inc. showed an increase of +3.0% in Long-Term Debt compared to the prior fiscal year.
- Disc Medicine, Inc. reported Stockholders Equity of $739.83 million for fiscal year 2025.
- Disc Medicine, Inc. showed an increase of +66.8% in Stockholders Equity compared to the prior fiscal year.
- Disc Medicine, Inc. reported R&D Expense of $170.64 million for fiscal year 2025.
- Disc Medicine, Inc. showed an increase of +76.5% in R&D Expense compared to the prior fiscal year.
- Disc Medicine, Inc. reported Operating Income of -$236.02 million for fiscal year 2025.
- Disc Medicine, Inc. showed a decrease of -81.9% in Operating Income compared to the prior fiscal year.
- Disc Medicine, Inc. reported Shares Outstanding of 37.89 million shares for fiscal year 2025.
- Disc Medicine, Inc. showed an increase of +26.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: